Needham & Company Sees 2nd-Half Qsymia Ramp for Vivus (VVUS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
VIVUS, Inc. (VVUS) Misses Q4 Views on Heftier Qsymia Costs; Analysts Comment
February 26, 2013 9:23 AM ESTVIVUS, Inc. (Nasdaq: VVUS) is lower in early trading Tuesday following fourth-quarter results issued after markets closed Monday.
The company reported a loss of 56 cents per share on revs of $1.97 million. The Street was looking for a loss of 44 cents per share and revs of $3.09 million.
For more color on the results, click here.
Analysts are out with a few... More
UPDATE: VIVUS, Inc. (VVUS) Posts Q4 Loss of 56c/Share
February 25, 2013 4:16 PM EST(Updated - February 25, 2013 4:48 PM EST)
VIVUS, Inc. (NASDAQ: VVUS) reported Q4 EPS of ($0.56), $0.12 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $1.97 million versus the consensus estimate of $3.09 million.
Qsymia sales were $2 million in the fourth quarter. For the four-weeks ended February 15, 2013, about 17,383 Qsymia prescriptions were shipped, which compares with 13,037 on January 18,... More
